Intravenous leiomyomatosis is a rare growth of smooth muscle that starts in or near the uterus and grows inside veins. It most often affects adult women, especially those with a current or past history of uterine fibroids. Many living with intravenous leiomyomatosis have no symptoms at first, but early symptoms of intravenous leiomyomatosis can include pelvic pressure, abnormal bleeding, leg swelling, shortness of breath, or chest discomfort if the growth reaches large veins or the heart. Not everyone will have the same experience. Treatment usually involves surgery to remove the growth, and the outlook is often good when it is found and fully removed, though serious complications and rarely death can happen if it extends into the heart or lungs.
How many people live with Intravenous leiomyomatosis?
There is no reliable recent estimate of how many people are living with intravenous leiomyomatosis worldwide or in the United States; sources such as Orphanet and the National Organization for Rare Disorders describe it as extremely rare but do not give a firm count (Orphanet, 2024; NORD, 2024). In practice, it is known mostly from individual case reports rather than large tracking systems, so both global and U.S. numbers remain unclear.
Overview
Intravenous leiomyomatosisSymptoms
Intravenous leiomyomatosis often causes no symptoms at first. When symptoms happen, people with intravenous leiomyomatosis may notice heavy menstrual bleeding, pelvic pain, or a feeling of pressure. If it reaches larger veins or the heart, shortness of breath, chest discomfort, or fainting can occur.
Outlook and prognosis
Intravenous leiomyomatosis is usually noncancerous, but it can grow inside veins and sometimes reach the heart or lungs if not fully removed. Outlook is often good with complete surgery, though long-term follow-up matters because regrowth can happen.
Causes and risk factors
The exact cause of intravenous leiomyomatosis is unclear, but it likely starts from uterine smooth muscle cells, often in people with fibroids. Risk appears higher during the reproductive years, with estrogen exposure, and in those with a history of uterine surgery.
Genetic influences
Genetics do not appear to be a main driver of Intravenous leiomyomatosis in most people. It is usually considered a sporadic growth, though rare genetic changes in tumor cells may be found during testing.
Diagnosis
Intravenous leiomyomatosis is usually diagnosed with imaging, often ultrasound, CT, or MRI, to map how far it extends. Doctors confirm the diagnosis of intravenous leiomyomatosis by examining tissue removed during surgery under a microscope.
Treatment and drugs
Intravenous leiomyomatosis is usually treated with surgery to remove the vein-growing smooth muscle tissue, often with both gynecology and vascular surgery teams involved. Some also need a hysterectomy and ovary removal. Ongoing imaging helps watch for regrowth.
Symptoms
Intravenous leiomyomatosis can be easy to miss because it often starts with symptoms that feel a lot like uterine fibroids. The early symptoms of intravenous leiomyomatosis may include heavier periods, pelvic pressure, or a feeling of fullness in the lower belly. If the growth extends into larger veins and toward the heart, symptoms can shift to leg swelling, shortness of breath, or heartbeat changes.
Intravenous leiomyomatosis may cause no clear symptoms at first and is sometimes found during imaging, surgery, or follow-up for fibroids. That can make the condition hard to recognize until it has grown further.
Menstrual bleeding can be heavier, longer, or more disruptive than usual when intravenous leiomyomatosis is linked with a uterine mass. Over time, blood loss can leave you feeling tired, weak, or lightheaded.
Dull pain, cramping, or a sense of pressure low in the pelvis is common. Some people notice discomfort with exercise, sex, or sitting for long stretches.
The lower abdomen may feel bloated or noticeably fuller, even without major weight gain. Clothes can feel tighter around the waist, and some people feel a constant sense of heaviness.
How people usually first notice Intravenous leiomyomatosis?
People usually first notice intravenous leiomyomatosis because of symptoms that seem to come from common uterine fibroids, such as heavy menstrual bleeding, pelvic pressure, a growing belly, or pain, while some have no symptoms at first and it is found unexpectedly during imaging or surgery. As the growth extends into veins, first signs of intravenous leiomyomatosis can also include swelling in the legs, shortness of breath, chest discomfort, dizziness, or fainting, especially if it reaches the large veins near the heart. Because these early clues can look like many other conditions, diagnosis often happens only after doctors connect the uterine findings with unusual vein or heart involvement on ultrasound, CT, or MRI.
Types of Intravenous leiomyomatosis
Intravenous leiomyomatosis is often described by how far the smooth muscle growth has traveled inside the veins, because that usually shapes what people feel day to day. In the earlier forms, many living with intravenous leiomyomatosis have no symptoms or only pressure, bleeding, or a pelvic mass, while more advanced spread can affect blood flow to the heart or lungs. Researchers describe these categories to better understand patterns of the condition.
Pelvic-limited
The growth stays in veins around the uterus or pelvis, and some people have no symptoms at all. Others may notice heavy bleeding, pelvic pressure, or a feeling of fullness similar to having fibroids.
Abdominal extension
In some types of intravenous leiomyomatosis, the growth extends into larger abdominal veins such as the ovarian veins or the inferior vena cava. This can cause leg swelling, abdominal discomfort, or a dragging sensation as blood flow becomes partly blocked.
Heart extension
This form, often called intracardiac intravenous leiomyomatosis, reaches the right side of the heart. People may develop shortness of breath, chest discomfort, palpitations, dizziness, or even fainting, especially with activity.
Lung vessel extension
Rarely, the growth reaches the blood vessels leading to the lungs. Symptoms can include worsening breathlessness, fatigue, and reduced exercise tolerance, which may look like other heart or lung problems at first.
Can I slow down the onset of symptoms?
At this time, there is no good evidence that lifestyle changes or medicines can meaningfully delay the start of symptoms from intravenous leiomyomatosis, a rare growth that can extend into veins from the uterus. General habits like staying active, not smoking, sleeping well, and managing blood pressure are good for overall health, but they have not been shown to reliably reduce the risk of this condition or prevent symptoms from starting, and research on prevention is still limited. There are no well-established screening or preventive drug guidelines for people without symptoms, but getting checked early for problems like unusual bleeding, pelvic pressure, chest discomfort, or shortness of breath may help doctors find it sooner and plan treatment.
What genetics can tell you about symptoms
For intravenous leiomyomatosis, genetics has not yet been shown to reliably predict which symptoms someone will have, how severe they will be, or when they will start. Researchers have found some genetic changes in these tumors that overlap with ordinary uterine fibroids, which suggests a shared biology, but these findings are not used in routine care to forecast symptoms. In practice, symptoms depend more on where the growth is, how far it has spread through veins, and whether it affects the heart or blood flow than on a known inherited genetic pattern.
Causes and risk factors
Intravenous leiomyomatosis usually begins from a uterine fibroid that grows into nearby veins. It is most often seen in people who have current or past fibroids, and estrogen may help the growth continue. Doctors also see it more often in adults in midlife and in some people who have had surgery for fibroids or the uterus. Researchers are still learning how these pieces fit together. Some tumors show gene changes that are not inherited, but no clear environmental or lifestyle cause for intravenous leiomyomatosis has been proven.
What are the most common causes or risk factors?
Intravenous leiomyomatosis most often develops in people who have or have had uterine fibroids, which are noncancerous growths in the womb, and it is seen most often during the reproductive years, when female hormone levels are higher. It is also more common in people with a past history of surgery for fibroids or the uterus, although the exact cause is still not fully understood. There is no clearly proven inherited risk, but these growths often show the same kind of gene changes seen in fibroids, which suggests they usually start from the same smooth muscle tissue.
Environmental and biological risk factors
Intravenous leiomyomatosis is a rare growth of smooth muscle tissue that can extend into veins, and its risk factors are not fully mapped out. Most of the better-known risk factors for intravenous leiomyomatosis are biological rather than environmental. Doctors often group risks into internal (biological) and external (environmental). For this condition, the strongest links are a history of uterine fibroids, hormone-sensitive growth, and certain gynecologic histories, while clear outside triggers have not been proven.
Many people with intravenous leiomyomatosis also have current or past uterine fibroids. This suggests the condition often develops in the same setting as benign smooth muscle growth in the uterus.
Intravenous leiomyomatosis often appears to be hormone-sensitive, especially to estrogen. It is seen more often during the reproductive years, and growth may be more likely in higher-estrogen states.
This condition is most often diagnosed in adults in their 30s to 50s. That age pattern supports a biological link with the years when uterine fibroids are also most common.
A history of surgery such as myomectomy or hysterectomy is often found in people later diagnosed with intravenous leiomyomatosis. This does not prove surgery causes it, but it is a repeated clinical association.
Genetic risk factors
Intravenous leiomyomatosis does not usually trace back to one inherited gene that runs strongly in families. Most cases appear to start from genetic changes that develop in smooth muscle cells, often in tissue related to uterine fibroids. It’s usually a combination of influences rather than one clear cause. Because this condition is rare, the genetic risk factors for intravenous leiomyomatosis are still being studied.
No single gene: Researchers have not confirmed one inherited gene that causes most cases of intravenous leiomyomatosis. In many people, the main DNA changes seem to be limited to the tumor itself rather than present in every cell of the body.
HMGA2 activity: A growth-control gene called HMGA2 is often unusually active in these tumors. This same pattern is also seen in some uterine fibroids, which supports a shared cell origin.
Chromosome changes: Some tumors show gains, losses, or rearrangements in pieces of chromosomes that help regulate cell growth. These changes may drive tumor growth, but they do not currently serve as a routine predictive test for family members.
Family pattern: A clear inherited family pattern has not been proven for most people with intravenous leiomyomatosis. Having relatives with uterine fibroids may reflect shared tendencies in smooth muscle growth, but it does not mean this rare condition will happen.
Lifestyle risk factors
Evidence on lifestyle risk factors for intravenous leiomyomatosis is very limited, and no everyday habit has been proven to directly cause it. What is known about lifestyle risk factors for intravenous leiomyomatosis mostly comes from its overlap with estrogen-sensitive uterine fibroids and from factors that can delay diagnosis or affect recurrence risk after treatment. In practice, lifestyle matters most through hormone exposure, body weight, activity patterns, and follow-up habits rather than through a single clear-cut trigger.
Higher body fat can increase estrogen production, which may support growth of estrogen-sensitive smooth muscle tissue. For people with intravenous leiomyomatosis, maintaining a healthy weight may help reduce one hormonal influence that could affect progression or recurrence.
Non-essential estrogen-containing therapies, such as some contraceptives or menopausal hormone treatments, may stimulate tumor growth in susceptible patients. Decisions about these medicines should be individualized, because how lifestyle affects intravenous leiomyomatosis often overlaps with hormone exposure choices.
Regular exercise can help with weight control and insulin sensitivity, which may indirectly lower estrogen-related stimulation. Activity has not been shown to prevent intravenous leiomyomatosis, but it may support recovery and long-term health after surgery.
A balanced eating pattern that helps prevent weight gain may indirectly influence estrogen levels and overall metabolic health. No specific food is known to cause or cure intravenous leiomyomatosis, but diet can matter when it affects body weight over time.
Risk prevention
There is no proven way to fully prevent intravenous leiomyomatosis, because it is a rare growth pattern of uterine smooth muscle tissue and its exact cause is still not clear. For many living with intravenous leiomyomatosis, prevention is really about lowering the chance of missed growth, spread inside veins, or serious complications. Prevention works best when combined with regular check-ups. This matters most for people who have had uterine fibroids, prior intravenous leiomyomatosis, or surgery for either condition.
There is no guaranteed way to stop intravenous leiomyomatosis from developing. Prevention is mainly focused on early detection and reducing the risk of complications if it does occur.
Many cases of intravenous leiomyomatosis are linked with uterine fibroids, so ongoing follow-up after fibroid treatment can be important. If symptoms return after surgery, repeat evaluation may help catch unusual regrowth earlier.
Early symptoms of intravenous leiomyomatosis can be easy to dismiss, such as pelvic pressure, abnormal bleeding, belly fullness, or shortness of breath if growth extends further. Getting these checked promptly may reduce the risk of delayed diagnosis.
If you have had intravenous leiomyomatosis before, your care team may recommend regular imaging to look for recurrence. This can help find new growth before it causes blockage in pelvic veins, the heart, or the lungs.
Can you prevent Intravenous leiomyomatosis?
There is no proven way to prevent intravenous leiomyomatosis, because doctors still do not fully understand why it happens. It often seems to start from common noncancerous growths in the uterus, called fibroids, but most people with fibroids never develop this rare condition, and no lifestyle change has been shown to stop it. What can help is paying attention to new symptoms and keeping up with routine gynecologic care, which may help it be found earlier even though it cannot reliably be prevented.
Transmission
Intravenous leiomyomatosis is not infectious, so it does not pass from one person to another through touch, sex, blood, coughing, or everyday contact. Although the growth can extend into veins within the body, that is not the same as being contagious.
For most people, Intravenous leiomyomatosis appears to develop in their own tissue rather than being “caught” from someone else. There is also no well-established genetic transmission of Intravenous leiomyomatosis, and most cases are not known to be passed from parent to child.
When to test your genes
For intravenous leiomyomatosis, genetic testing is not usually part of early detection or routine care because this condition is generally not inherited. It may be worth discussing testing if you have many fibroids at a young age, skin leiomyomas, or a family history of similar tumors or kidney cancer, which can point to a rare inherited syndrome.
Diagnosis
Intravenous leiomyomatosis is usually diagnosed after symptoms, a pelvic mass, or an unexpected finding on imaging leads to a closer look. Many living with intravenous leiomyomatosis have no symptoms at first, while others may notice pelvic pressure, abnormal bleeding, leg swelling, shortness of breath, or palpitations if the growth has extended through large veins. Doctors usually begin with an exam and imaging, then use tissue testing to confirm the diagnosis of intravenous leiomyomatosis. Some diagnoses are clear after a single visit, while others take more time.
Doctors ask about symptoms, past fibroids, prior uterine surgery, and any heart or breathing symptoms. A detailed family and health history can help, but intravenous leiomyomatosis is not usually an inherited condition.
A pelvic exam may suggest an enlarged uterus or pelvic mass. If the tumor has grown into major veins or the heart, the exam may also show leg swelling, a heart murmur, or signs of fluid buildup.
Ultrasound is often the first imaging test because it can show uterine fibroids and abnormal tissue in nearby veins. It helps identify where the growth may be starting, although it may not show the full extent.
These scans map how far the tumor extends through the pelvic veins, the large vein returning blood to the heart, and sometimes into the heart itself. This is often the key step in how intravenous leiomyomatosis is diagnosed and in planning treatment.
How is Intravenous leiomyomatosis diagnosed?
Intravenous leiomyomatosis is usually diagnosed with imaging tests that show a growth starting in the uterus and extending into nearby veins, most often an ultrasound, CT scan, or MRI. If doctors think it may have reached the large veins near the heart or the heart itself, they may also use a heart ultrasound to see how far it has spread. The diagnosis is usually confirmed when the growth is removed or sampled and looked at under a microscope, and genetic testing is not usually needed.
Stages of Intravenous leiomyomatosis
Intravenous leiomyomatosis is often described in stages based on how far the growth has extended through the veins. This helps doctors judge how serious it is, what symptoms may happen, and how complex treatment may be. Step by step, they look for the most likely explanations. In the early symptoms of intravenous leiomyomatosis, some people have no clear warning signs at all, while others notice heavy periods, pelvic pressure, shortness of breath, or palpitations as the growth reaches larger veins or the heart.
Stage 1
The growth is limited to the uterus or nearby pelvic veins. Many living with intravenous leiomyomatosis at this stage may have symptoms similar to fibroids, such as heavy bleeding, pelvic pain, or a feeling of fullness.
Stage 2
The growth has moved upward into larger abdominal veins but has not reached the heart. Some may still feel well, while others develop leg swelling, belly discomfort, or symptoms caused by reduced blood flow.
Stage 3
The growth extends into the large vein leading to the heart and may reach the right side of the heart. For many, this can mean chest discomfort, dizziness, shortness of breath, or fainting, especially with activity.
Stage 4
The growth reaches beyond the heart into the lung arteries or, rarely, further into the chest. This is the most advanced stage and can cause serious circulation or breathing problems that need urgent specialist care.
Outlook and prognosis
The outlook for people with intravenous leiomyomatosis is often favorable when the tumor is completely removed, because it is histologically benign even though it can behave aggressively by extending through veins and sometimes into the heart or lungs. Prognosis depends mainly on how far the growth has spread and whether surgery achieves clear removal, since incomplete excision is the main reason for recurrence. Reported recurrence can occur years later, so long-term imaging follow-up is usually recommended even after apparently successful treatment. When there is intracardiac extension, the condition can become life-threatening because of risks such as obstruction of blood flow, heart failure, arrhythmia, or pulmonary complications. Death is uncommon after timely diagnosis and successful surgery, but untreated advanced disease or difficult-to-resect cases can lead to serious morbidity and occasional mortality. Overall, early recognition and complete multidisciplinary surgical management are associated with the best outcomes.
Long-term effects
Intravenous leiomyomatosis can have lasting effects mainly because it may grow back or keep extending inside veins, even after treatment. Over time, daily routines may change if blood flow is partly blocked, causing swelling, shortness of breath, or reduced stamina. The long-term picture is often better when the growth is found and fully removed, but many living with intravenous leiomyomatosis need follow-up for years because late return is possible.
Intravenous leiomyomatosis can come back months or even years after surgery, especially if any of the growth remains in the veins. Because of this, long-term imaging follow-up is often part of the outlook.
Ongoing growth inside pelvic or abdominal veins can slow blood flow and lead to leg swelling, pelvic pressure, or discomfort. For many, this can mean heaviness after standing or walking for a while.
If the growth reaches large veins near the heart or enters the heart itself, it can cause palpitations, dizziness, chest discomfort, or fainting. In more serious cases, it may interfere with how well the heart fills and pumps blood.
When intravenous leiomyomatosis extends toward the heart and lung circulation, some people develop shortness of breath or poor exercise tolerance over time. These symptoms can be subtle at first, which is one reason early symptoms of intravenous leiomyomatosis are sometimes missed.
How is it to live with Intravenous leiomyomatosis?
Living with intravenous leiomyomatosis can feel unsettling because a growth that starts from uterine smooth muscle can travel through veins, so some people live with pelvic pressure, heavy bleeding, fatigue, or shortness of breath, while others feel little until it is found on imaging or during surgery. Daily life may be shaped by medical appointments, scans, major surgery, and the stress of follow-up, since even after treatment many living with intravenous leiomyomatosis need long-term monitoring for recurrence. For partners, family, and other loved ones, this often means helping with transportation, recovery, and the emotional weight of uncertainty, but with expert care and careful surveillance, many people are able to return to much of their usual routine.
Treatment and drugs
Treatment for intravenous leiomyomatosis usually centers on surgery, because this condition involves benign smooth muscle growth that can extend into veins and, in some people, reach the heart or large blood vessels. The main goal is to remove as much of the growth as safely possible, often with a team that may include gynecologic, vascular, and heart surgeons depending on how far it has spread. Because intravenous leiomyomatosis is often linked to estrogen, doctors may also recommend removing the uterus and ovaries or using hormone-lowering medicines in selected cases, especially if surgery cannot remove everything or if the growth comes back. Not every treatment works the same way for every person, so follow-up imaging over time is important to check for recurrence and guide the next steps.
Can you cure Intravenous leiomyomatosis?
Intravenous leiomyomatosis, a rare growth that usually starts in the uterus and spreads into veins, can sometimes be cured if surgery removes all of the growth. There is no pill or other medicine that reliably cures it, but treatment can control it, ease symptoms, and lower the chance of it growing back. Even after treatment, many people living with this condition need regular follow-up because it can return.
Non-drug treatment
Intravenous leiomyomatosis can affect daily life in unexpected ways, especially when growth extends through pelvic veins or even toward the heart and causes pressure, swelling, breathlessness, or fatigue. Treatment is usually centered on removing as much of the growth as safely possible, because medicines alone are not the main treatment for this condition. For many, treatment begins not at the pharmacy, but in careful planning with gynecology, vascular, and heart surgeons. Follow-up imaging also matters, since intravenous leiomyomatosis can come back after treatment.
Surgery is the main non-drug treatment for intravenous leiomyomatosis. The goal is to remove the growth from the uterus, pelvis, and affected veins as completely as possible while protecting blood flow and nearby organs.
Many living with intravenous leiomyomatosis need a coordinated team because the growth can involve pelvic veins, the large vein to the heart, or the heart itself. Joint planning by gynecologic, vascular, and sometimes cardiothoracic surgeons helps choose the safest approach.
Regular scans such as ultrasound, CT, or MRI are used before and after treatment to map the growth and watch for return. This is especially important when checking for early signs of recurrent intravenous leiomyomatosis, even if you feel well.
Some people need treatment in more than one step rather than one long operation. Not every approach works the same way, and staging can make surgery safer when the growth extends over a long distance or into the chest.
Your genes may have an impact on how drugs work for you
For people living with intravenous leiomyomatosis, treatment is usually centered on surgery, and medicines are sometimes used to lower hormone signals that can help this growth keep going. In day-to-day care, there is no well-established evidence that common inherited genetic differences routinely change how these medicines work in a way that guides treatment, so genetic drug-response testing is not a standard part of care for this condition. If medicine is being considered, doctors usually base choices on the size and spread of the growth, hormone sensitivity, side effects, and future pregnancy plans rather than on a drug-response gene test.
Pharmacological treatments
For many living with intravenous leiomyomatosis, treatment usually centers on surgery rather than medicine. There is no standard drug treatment for intravenous leiomyomatosis, but hormone-lowering medicines may be used in selected cases, such as before surgery, after surgery if there is concern about regrowth, or when an operation is not possible right away. These drugs are used because many of these tumors appear to be influenced by estrogen. Not everyone responds to the same medication in the same way.
There is no single medicine proven to cure intravenous leiomyomatosis on its own. Drug treatment is usually an added approach, not the main treatment, and the plan depends on tumor size, symptoms, and whether surgery can be done.
Leuprolide and goserelin are medicines that lower estrogen levels and may help slow tumor growth or shrink the mass somewhat before surgery. Sometimes medicines are taken short-term (acute treatment), while others are used long-term (maintenance therapy).
Letrozole and anastrozole lower the body's estrogen production and may be considered after surgery or when intravenous leiomyomatosis comes back. These drugs are used more often after menopause, but some specialists may also use them in other settings with careful follow-up.
Tamoxifen, medroxyprogesterone, and megestrol have been used in some reports, but their benefit in intravenous leiomyomatosis is less clear and they are not routine first-choice options. Because evidence is limited, doctors weigh possible side effects and the tumor's hormone sensitivity before using them.
Genetic influences
Intravenous leiomyomatosis is usually linked to genetic changes that develop in the tumor cells over time, rather than to a gene change inherited from a parent. Researchers think some of these changes overlap with those seen in uterine fibroids, which helps explain why this rare condition often begins in or near the uterus. It’s natural to ask whether family history plays a role. Right now, most evidence suggests intravenous leiomyomatosis is not strongly hereditary, and many people with it do not have a clear family pattern. Put simply, the genetic causes of intravenous leiomyomatosis seem to be mostly acquired, not passed down through families. If your personal or family history includes several unusual smooth muscle tumors or other rare growths, your doctor may still consider a genetics referral, but that is not routine for most people with intravenous leiomyomatosis.
Is Intravenous leiomyomatosis genetic?
Genetics do not appear to be a main driver of Intravenous leiomyomatosis in most people. It is usually considered a sporadic growth, though rare genetic changes in tumor cells may be found during testing.
Having a genetic risk is not necessarily a diagnosis
Variants in genes are common and are a normal part of human biology. Most do not directly affect health and are simply part of the natural variation seen among people. In many genes, having a variant tied to a condition points to a possible link, not a certain diagnosis, especially when more than one gene and environmental factors play a role. Still, in some situations, one well-understood variant in a particular gene is enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
For people living with intravenous leiomyomatosis, treatment is usually shaped more by where the growth has reached and whether hormones seem to be fueling it than by a blood genetic test, so surgery is often the main treatment and medicines may play a supporting role. Researchers have found that many intravenous leiomyomatosis tumors share some of the same gene changes seen in uterine fibroids, which may help explain why hormone-lowering or estrogen-blocking treatment can sometimes help before or after surgery in selected cases. Genetics is only one factor, though, and doctors still rely much more on imaging, symptoms, age, and pregnancy goals when planning care. At this point, there is no standard pharmacogenetic test that can reliably tell doctors which drug will work best for intravenous leiomyomatosis, and inherited genetic testing is not routine for most people with this condition. If you are looking into how genes affect treatment for intravenous leiomyomatosis, their biggest role today is in helping researchers understand why the tumor grows, rather than in choosing a specific medicine for everyday care.
Interactions with other conditions
People with intravenous leiomyomatosis often first notice problems that seem to overlap with more common conditions, such as uterine fibroids, heavy periods, pelvic pressure, or a swollen abdomen. Another important aspect is how it may link with other diseases: when this growth extends through veins toward the heart or lungs, it can cause symptoms that look like heart disease or a blood clot, including shortness of breath, chest discomfort, dizziness, or fainting. This means the early symptoms of intravenous leiomyomatosis are sometimes mistaken for a gynecologic problem alone, or for a circulation problem unrelated to the uterus. Many living with intravenous leiomyomatosis also need doctors to check carefully for related issues such as anemia from heavy bleeding, and for strain on the heart if the tumor has grown into large veins. Because these overlaps can affect both diagnosis and treatment, care is often safest when gynecology, imaging specialists, and sometimes heart or vascular teams work together.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Intravenous leiomyomatosis?
Intravenous leiomyomatosis can be mistaken for common uterine fibroids or other causes of heavy periods, pelvic pain, or a feeling of fullness in the belly, and sometimes for cancer of the uterus or ovaries when scans show a mass. If it has grown into large veins or toward the heart, it can also look like a blood clot or a heart growth, especially in people with leg swelling, shortness of breath, chest pain, or fainting.
History
For many living with intravenous leiomyomatosis, one of the hardest parts is that the condition can sound unfamiliar even after several medical visits. It often came to medical attention only when a growth had already extended through veins, sometimes causing symptoms that seemed unrelated at first, such as pelvic pressure, heavy periods, swelling, shortness of breath, or episodes that looked more like a heart or circulation problem than a growth starting in the uterus.
Doctors began describing this condition in the late 19th and early 20th centuries, when surgeons and pathologists noticed an unusual pattern: tissue that looked like a fibroid under the microscope was growing inside veins rather than staying within the wall of the uterus. Early reports were based on what was seen during surgery or at autopsy, so understanding was limited. Over time, it became clear that intravenous leiomyomatosis could behave in a very distinctive way, traveling along blood vessels and, in some cases, reaching large veins near the heart.
Once thought to be exceptionally rare, intravenous leiomyomatosis is now more widely recognized because imaging and modern surgery have made it easier to identify. That has changed the picture in a practical way. In the past, someone might have been treated only for fibroids and later found to have disease still present in the veins; today, scans such as ultrasound, CT, and MRI can often show the full extent before treatment begins.
The history of intravenous leiomyomatosis also reflects a broader shift in medicine: doctors moved from describing what they could see to understanding how the condition behaves over time. Researchers later identified that it is linked to abnormal growth of smooth muscle cells, even though it is not usually classified as a typical cancer. This matters because the condition can act locally aggressive despite looking benign under the microscope.
In recent decades, awareness has grown among gynecologists, vascular surgeons, heart surgeons, and radiologists, because treatment often depends on recognizing the condition across more than one part of the body. Knowing this history helps explain why early symptoms of intravenous leiomyomatosis may be mistaken for more common problems at first, and why careful imaging and follow-up are now such important parts of care.